Lobe Sciences arranges $137,130 (U.S.) debt settlement

Executive Summary

• Lobe Sciences Ltd. will settle $137,130 USD of related‑party liabilities by issuing 3,837,686 common shares at C$0.05 per share.
• The transaction is intended to strengthen the balance sheet, preserve cash for growth initiatives, and improve stock liquidity.
• Shares are subject to a four‑month statutory hold period and the settlement requires approval from the Canadian Securities Exchange.

Key Details

• Liability Settlement Amount: US $137,130 (CAD $191,884.32).
• Equity Issuance: 3,837,686 common shares at C$0.05 per share.
• Counterparty: Clearway Global LLC – related party that holds >20% of Lobe’s outstanding common shares and is controlled by a director/officer.
• Regulatory Treatment: Exempt from formal valuation and minority‑shareholder approval under MI 61‑101 sections 5.5(a) and 5.7(1)(a).
• Hold Period: Statutory hold of four months from issuance per Canadian securities laws and CSE policies; additional restrictions may apply in other jurisdictions.
• Closing Condition: Settlement pending approval by the Canadian Securities Exchange.
• Purpose: Convert debt to equity, bolster balance sheet, preserve cash for strategic growth, and potentially enhance share liquidity given insider concentration.

Notable Quotes

“By converting liabilities into equity, Lobe strengthens its balance sheet and aligns stakeholders with our long‑term growth strategy,” – Dr. Fred D. Sancilio, CEO & Chairman.
“This structure enhances operational flexibility, reflects our commitment to disciplined capital management and may improve stock liquidity, particularly given the concentration of shares held by insiders and strategic partners.” – Dr. Fred D. Sancilio.